N/A N=17 A Physical Activity Program in End-state Liver Disease
End-stage Liver Disease (ESLD) · Liver Transplant · Sarcopenia
Primary: Physical Fitness - VO2 — -1; -3 mL oxygen/kg/min — p=0.49
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Adaptive, Real-time, Intelligent System to Enhance Self-care of Chronic Disease
Diabetes Mellitus, Type 1
Primary: Time in Range (%) — 64 percentage of time (minutes)
N/A N=100 the Impact of Noise on Requirements of Anesthetics During General Anesthesia
Anesthesia
Primary: Requirements of the Inhalational Anesthetic Desflurane, Measured in Expiratory Volume Percentage, to Maintain a BIS-Index Triggered Depth of Anesthesia — 3.6; 3.7…
N/A N=65 Thoracic Paravertebral Block Using Ropivacaine and Dexmedetomidine
Pain, Postoperative
Primary: Postoperative Pain (Pain Scores) Intensity Measure — 1; 3 units on a scale — p=0.001
Phase 2 N=68 Chemotherapy for Participants With Lymphoma
Lymphoma, Large Cell, Diffuse
Primary: Percent of Participants With Progression Free Survival (PFS) After 1 Year Treatment — 16.4 percentage of participants
Phase 2 N=79 Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain
Pain
Primary: Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine — 6.54; 0.25; 4.06 score on a scale
Phase 2 N=13 Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
Human Immunodeficiency Virus
Primary: Number of Participants With Severe and Life-threatening Adverse Events (AEs) — 0; 4; 4; 0 Participants
N/A N=428 Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5
Heart Failure, Congestive
Primary: Efficacy Endpoint: Ventilatory Anerobic Threshold (VAT) — 28; 38 Participants — p=0.31
N/A N=65 Ocular Characteristics in Contact Lens and Spectacle Wear
Visual Acuity
Primary: Non-Invasive Break Up Time (NIBUT) or Non-Invasive Keratograph Break Up Time (NIKBUT) — 8.28; 11.10 Seconds
Phase 2 N=118 Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) — 0.043; 0.016 Liters — p=0.7374
N/A N=504 Condom Performance in a Longitudinal Enhanced Assessment of User Experiences
HIV
Primary: Sexual Pleasure Scale Score for Fitted Versus Standard Condoms — 71.52; 70.13 score on a scale — p=<0.05
N/A N=78 Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Procedures
Oxygen Deficiency · Desaturation of Blood · Hypoventilation
Primary: Number of Surgical Interruptions — 0.645; 0.302 Interruptions — p=0.206
Phase 2 N=28 Enzastaurin for Patients With Metastatic Colorectal Cancer
Colonic Neoplasms
Primary: Percentage of Participants With Progression Free Survival (PFS) at 6 Months — 27.50 percentage of participants
N/A N=789 Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants That Reported COPD Symptom Burden- Measured Using COPD Assessment Test (CAT) Questionnaire — 13.27; 11.34; 51.28; 43.58 Percentage of…
N/A N=142 Ab Interno Gelatin Stent With Mitomycin C Using Targeted Supra-tenon's Placement
Glaucoma
Primary: Postoperative Intraocular Pressure Changes Between Targeted Supratenon's Placement of XEN-45 Gelatin Stent and Nontargeted Placement. — 20; 15 Participants